Treating relapsed and refractory metastatic germ cell tumours with high-dose chemotherapy with carboplatin and etoposide and autologous haematopoietic stem cell transplantation

Erturk I., Karadurmus N., Kiziloz H., Acar R., Yildiz B., Aykan M. B., ...Daha Fazla

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.27, sa.7, ss.1657-1664, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 7
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1177/1078155220964540
  • Dergi Adı: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Sayfa Sayıları: ss.1657-1664
  • Anahtar Kelimeler: Germ cell tumour, stem cell, transplantation, TESTICULAR CANCER, SALVAGE TREATMENT, SURVIVAL, RESCUE, TRIAL
  • Ankara Üniversitesi Adresli: Evet

Özet

Introduction and aim To demonstrate the real-life data about patients who underwent AHSCT due to GCT. Methods Between November 2016 and April 2020, 64 patients who received CE as high-dose chemotherapy for AHSCT in the Gulhane Education and Research Hospital were included in the study. Sixty-one patients received one AHSCT with CE chemotherapy regimen. Survival data and clinical characteristics were evaluated retrospectively. Results The mean age of the patients were 31.9 +/- 9 (min-max:18-55). With a median follow-up of 10.7 +/- 8.7 months, the 1-year progression-free survival (PFS) rate was 57.8%, and the 1-year overall survival rate was 77.5%. Median overall survival (OS) and progression-free survival (PFS) times were 21.5 +/- 1.8 (95% CI: 14.5-33.4) and 20 +/- 2 months, respectively. The response rate was 72%. There were three treatment-related deaths. Conclusion This sizeable single-centre study shows that patients with relapsed metastatic GCT are curable by CE as high dose chemotherapy plus AHSCT with reliable toxicity even for a single cycle.